Prostate Cancer - To screen, or not to screen, is that the question?

BMC Urology

Volumn 8, Issue 1, 2008, Pages

  Rosser, Charles J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; CANCER THERAPY; HUMAN; NOTE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TREATMENT INDICATION; EDITORIAL; MALE; MASS SCREENING; PROSTATE TUMOR;

HUMANS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS;

EID: 58849166823     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-8-20     Document Type: Note

References (15)

1. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? TA Stamey M Caldwell JE McNeal R Nolley M Hemenez J Downs, J Urol 2004 172 4 Pt 1 1297 301 10.1097/01.ju.0000139993.51181.5d 15371827
2. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. CJ Rosser DA Kuban SJ Lee LB Levy C Pettaway AM Kamat R Chichakli A Lee RM Cheung R Sanchez-Ortiz LL Pisters, J Natl Med Assoc 2004 96 7 939 344 15253325
3. Screening for prostate cancer (PC) - an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). FH Schröder, Urol Oncol 2008 26 5 533 41 18774469
4. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. G Bartsch W Horninger H Klocker A Reissigl W Oberaigner D Schönitzer G Severi C Robertson P Boyle Tyrol Prostate Cancer Screening Group, Urology 2001 58 417 424 10.1016/S0090-4295(01)01264-X 11549491
5. Radical prostatectomy versus watchful waiting in early prostate cancer. A Bill-Axelson L Holmberg M Ruutu M Häggman SO Andersson S Bratell A Spångberg C Busch S Nordling H Garmo J Palmgren HO Adami BJ Norlén JE Johansson Scandinavian Prostate Cancer Group Study No. 4, N Engl J Med 2005 352 1977 1984 10.1056/NEJMoa043739 15888698
6. Decline in prostate cancer mortality from 1980 to and an update on incidence trends in Olmstead County, Minnesota. RO Robert EJ Bergstralh SK Katusic MM Liber SJ Jacobsen, J Urol 1997 161 529 533 10.1016/S0022-5347(01) 61941-4
7. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 2 71 96 Epub 2008 Feb 20 10.3322/CA.2007.0010 18287387
8. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. RM Hoffman FD Gilliland JW Eley LC Harlan RA Stephenson JL Stanford PC Albertson AS Hamilton WC Hunt AL Potosky, J Natl Cancer Inst 2001 93 388 395 10.1093/jnci/93.5.388 11238701
9. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. DV Makarov BJ Trock EB Humphreys LA Mangold PC Walsh JI Epstein AW Partin, Urology 2007 69 6 1095 101 17572194 10.1016/j.urology.2007.03.042
10. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. F Dong MW Kattan EW Steyerberg JS Jones AJ Stephenson FH Schröder EA Klein, J Urol 2008 180 1 150 4 discussion 154. Epub 2008 May 15 10.1016/j.juro.2008.03.053 18485398
11. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. AV D'Amico MH Chen KA Roehl WJ Catalona, N Engl J Med 351 2 125 35 2004 Jul 8 10.1056/NEJMoa032975 15247353
12. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. A Ochiai P Troncoso ME Chen J Lloreta RJ Babaian, J Urol 2005 174 6 2164 8 discussion 2168 10.1097/01.ju.0000181211.49267.43 16280756
13. Expectant management with selective delayed intervention for favorable risk prostate cancer. L Klotz, Urol Oncol 2002 7 5 175 9 10.1016/S1078-1439(02) 00183-7 12644212
14. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. HB Carter A Kettermann C Warlick EJ Metter P Landis PC Walsh JI Epstein, J Urol 2007 178 6 2359 64 discussion 2364-5. Epub 2007 Oct 22 10.1016/j.juro.2007.08.039 17936806
15. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer. S Anai K Nakamura MN Chang J Pendleton S Yacoub CJ Rosser, J Health Care Poor Underserved 2008 19 1 164 70 10.1353/hpu.2008.0024 18263992